STOCK TITAN

Windward Bio Lists on Nasdaq, Shares Up 68% on Debut

(Very High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Windward Bio (WWB) began trading on the Nasdaq Global Select Market on November 13, 2026, following its initial public offering. The offering priced at $17.00 per share and sold approximately 10.29 million ordinary shares. Gross proceeds totaled $225 million, including a $50 million concurrent private placement from Sanofi. First-day closing market capitalization was approximately $1.69 billion.

Proceeds will primarily support clinical development of WIN378 and WIN027. WIN378 is in Phase 2/3 asthma and Phase 2 COPD studies; positive interim Phase 2 asthma data were reported in September 2026. Windward expects WIN378 asthma data in the first half of 2027, COPD data in the second half of 2027, and Phase 3 asthma data in the first half of 2029.

Loading...
Loading translation...
12 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 2 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate pointIPO and concurrent Sanofi private placement raised $225 million in gross proceeds, including $50 million from Sanofi. 14% of market cap
  • Moderate pointWIN378 positive interim Phase 2 asthma data reported in September 2026 supported twice-yearly dosing.
  • Minor pointShares rose 68% on debut; first-day closing market capitalization was approximately $1.69 billion.
  • Minor pointWIN378 development includes ongoing Phase 2/3 asthma and Phase 2 COPD studies.
  • Minor pointWIN027 is in Phase 1 development, adding a second clinical-stage program.
7 minor points
  • Minor point. Forward-looking: it has not happened yet and may not happen.Proceeds primarily support WIN378 clinical development, including asthma studies and the Phase 2 COPD study.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Proceeds support planned WIN027 Phase 2b COPD and Phase 2 atopic dermatitis trials.
  • Minor point. Forward-looking: it has not happened yet and may not happen.WIN027 atopic dermatitis trial enrollment is expected in the first half of 2027.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Proceeds also support advancing a bispecific program toward Investigational New Drug application readiness.
  • Minor point. Forward-looking: it has not happened yet and may not happen.WIN378 Phase 2 asthma top-line data are expected in the first half of 2027.
  • Minor point. Forward-looking: it has not happened yet and may not happen.WIN378 Phase 2 COPD data are expected in the second half of 2027.
  • Minor point. Forward-looking: it has not happened yet and may not happen.WIN378 Phase 3 asthma data are expected in the first half of 2029.

Negative

  • Moderate pointIPO issuance of approximately 10.29 million ordinary shares at $17.00 each dilutes existing holders.
  • Minor pointLicensing rights for both core programs exclude Greater China and certain Asian markets.

News Explained

The release adds a reported first-day trading result: Windward Bio says its shares rose 68% on their November 13, 2026 Nasdaq debut, after the IPO priced at $17.00 per share.

Key Figures

First-day share gain: 68% IPO price: $17.00 per share Gross proceeds: $225 million +5 more
First-day share gain
68%
Nasdaq debut
IPO price
$17.00 per share
Initial public offering
Gross proceeds
$225 million
Offering proceeds, including the concurrent private placement
Private placement
$50 million
Concurrent placement from Sanofi
Market capitalization
approximately $1.69 billion
At the close of the first trading day
Top-line asthma data
First half of 2027
WIN378 Phase 2 asthma data (POLARIS-1)
COPD data
Second half of 2027
WIN378 Phase 2 data (SIRIUS)
Asthma data
First half of 2029
WIN378 Phase 3 data

Key Terms

initial public offering, monoclonal antibody, thymic stromal lymphopoietin, bispecific antibody, +1 more
5 terms
initial public offering financial
"The company priced its initial public offering at $17.00 per share"
An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.
monoclonal antibody medical
"WIN378, an ultra-long-acting, fully human monoclonal antibody"
A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.
thymic stromal lymphopoietin medical
"antibody against thymic stromal lymphopoietin (TSLP)"
Thymic stromal lymphopoietin (TSLP) is a small signaling protein the body uses like an alarm bell to alert and steer immune cells, especially in barrier tissues such as the lungs and skin. It matters to investors because drugs that block or measure TSLP can reduce allergic inflammation and other immune-driven diseases; successful therapies or tests can drive regulatory approvals, market adoption and company value much like a new product that solves a widespread problem.
bispecific antibody medical
"WIN027, a clinical-stage bispecific antibody"
A bispecific antibody is a specially designed protein that can attach to two different targets at the same time. Think of it as a custom-made connector that brings two things together—such as a disease cell and an immune system component—helping the body fight illnesses more effectively. For investors, understanding bispecific antibodies is important because they represent innovative therapies that could lead to new treatments and potentially lucrative market opportunities.
investigational new drug regulatory
"moving the bispecific program to Investigational New Drug (IND) readiness"
An investigational new drug is a medication that is still being tested in clinical trials to determine if it is safe and effective for treating a specific condition. For investors, it represents a potential breakthrough that could lead to a new treatment and significant financial gains if successful, but also carries risks since it has not yet been approved for widespread use.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Pivotal bioVenture Partners China-backed biotech built under the NewCo model on China-licensed assets debuts on Nasdaq less than two years after founding

SHANGHAI, Nov. 16, 2026 /PRNewswire/ -- Windward Bio Group AG (Nasdaq: WWB), a clinical-stage biotechnology company and a portfolio company of Pivotal bioVenture Partners China, began trading on the Nasdaq Global Select Market on Nov. 13, 2026. The company priced its initial public offering at $17.00 per share and sold approximately 10.29 million ordinary shares, raising $225 million in gross proceeds, including a $50 million concurrent private placement from Sanofi. Windward closed its first day of trading with a market capitalization of approximately $1.69 billion.

Windward was founded in 2024 by serial entrepreneur Luca Santarelli, M.D., and his team, whose prior companies VectivBio and Therachon were both acquired. Since inception, the company has raised $365 million, including a $200 million Series A in January 2025 and a $165 million crossover financing in May 2026. Pivotal bioVenture Partners is among the investors that have backed Windward through every financing round since its earliest days, from formation to a Nasdaq listing in under two years.

Headquartered in Basel, Switzerland, Windward develops ultra-long-acting antibody medicines for serious respiratory and dermatologic diseases, including asthma, chronic obstructive pulmonary disease (COPD) and atopic dermatitis. Its lead program, WIN378, is an ultra-long-acting, fully human monoclonal antibody against thymic stromal lymphopoietin (TSLP) now advancing through POLARIS-1, a Phase 2/3 study in asthma, and SIRIUS, a Phase 2 study in COPD. Designed for twice-yearly dosing, versus the once-every-four-weeks regimen of currently approved agents, WIN378 could meaningfully ease the long-term treatment burden for patients with chronic airway disease. In September 2026, the company reported positive interim Phase 2 data supporting twice-yearly dosing of WIN378 in asthma. Windward's pipeline also includes WIN027, a clinical-stage bispecific antibody targeting TSLP and IL-13 now in Phase 1 development.

The global rights (excluding Greater China and certain Asian markets) to both of Windward's core programs were licensed from Chinese biopharmaceutical companies. WIN378 (HBM9378/SKB378) came out of a co-development program between Harbour BioMed and Kelun-Biotech, while WIN027 (QX027N) was licensed from Qyuns Therapeutics. Windward is the latest example of China-originated drug candidates reaching global capital markets through license-out deals.

Windward is a leading case of the NewCo model in the current wave of Chinese biotech going global: a global investment firm leads the spin-out and licensing of a Chinese company's pipeline asset, sets up a new entity overseas, and arms it with international capital and an experienced operating team to run clinical development and commercialization worldwide — typically excluding Greater China. Pivotal bioVenture Partners China's practice has been a consistent investor, participating in the $200 million Series A in January 2025, increasing its position in the $165 million crossover round in May 2026, and remaining a shareholder through the IPO. In less than two years, Windward has completed the full path from "China asset licensing" to "NewCo formation" to "global financing" to "IPO listing," plugging China-originated innovation into the global value chain.

According to company disclosures, net proceeds from the offering will be used primarily for completing core clinical development of WIN378, including the Phase 2/3 and confirmatory asthma studies and the Phase 2 COPD study; advancing the global Phase 2b COPD trial and the Phase 2 atopic dermatitis trial of WIN027, the latter expected to begin enrollment in the first half of 2027; moving the bispecific program to Investigational New Drug (IND) readiness; and funding working capital and general corporate purposes. After the offering, the pipeline is expected to reach three key data milestones: top-line Phase 2 asthma data for WIN378 (POLARIS-1) in the first half of 2027, Phase 2 COPD data (SIRIUS) in the second half of 2027, and Phase 3 asthma data in the first half of 2029.

For Pivotal bioVenture Partners, Windward Bio is a prime example of the NewCo model at work — China-originated innovation matched with global capital and world-class execution. From the start, the firm saw WIN378 and WIN027 as potential best-in-class, ultra-long-acting biologics for serious respiratory and dermatologic diseases, and it has backed Luca Santarelli and his team through every financing round since formation. The Nasdaq listing in under two years — putting the value of assets originated by its Chinese partners Harbour BioMed, Kelun-Biotech and Qyuns Therapeutics on the global stage — is a milestone for Pivotal, which plans to keep supporting Windward through its next phase of growth.

About Windward Bio

Windward Bio is a clinical-stage biotechnology company with deep drug discovery, development and commercialization experience, focused on transforming the treatment of serious immunological diseases, including respiratory and dermatologic conditions. Its lead program, WIN378, is an ultra-long-acting anti-TSLP monoclonal antibody with best-in-class potential, now in Phase 2/3 clinical trials for asthma. The company's pipeline also includes WIN027, a clinical-stage, long-acting anti-TSLP×IL-13 bispecific antibody with broad therapeutic potential across inflammatory diseases, now in Phase 1. Windward is also building a long-acting bispecific antibody discovery pipeline focused on validated targets in respiratory and dermatologic diseases.

About Pivotal bioVenture Partners

Pivotal bioVenture Partners was founded by Hong Kong's Nan Fung Group. Since launching its U.S. operations in 2017 and its China practice in 2018, Pivotal has built broad international reach and global resource-coordination capabilities. The firm seeks out innovative products and technologies worldwide, founding and investing in leading life-science companies in Greater China to meet growing medical needs in global markets — particularly China. Pivotal invests across biopharmaceuticals, medical devices and healthcare services. Its team of seasoned life-science investors and entrepreneurs brings deep industry experience in company creation and venture investment.

Contact:
Phone: +86-21-68503033
Email: info@pivotalbiovp.cn

Cision View original content:https://www.prnewswire.com/news-releases/windward-bio-lists-on-nasdaq-shares-up-68-on-debut-302940459.html

SOURCE Pivotal bioVenture Partners China

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much did Windward Bio raise in its IPO and Sanofi placement?

Windward Bio raised $225 million in gross proceeds, including a $50 million concurrent private placement from Sanofi. The IPO priced at $17.00 per share and sold approximately 10.29 million ordinary shares.

When does Windward Bio expect its next WIN378 clinical results?

Windward expects Phase 2 asthma top-line data in the first half of 2027, Phase 2 COPD data in the second half of 2027, and Phase 3 asthma data in the first half of 2029. The asthma study is POLARIS-1, while the COPD study is SIRIUS.

Where did Windward Bio license WIN378 and WIN027?

WIN378 originated in a co-development program between Harbour BioMed and Kelun-Biotech, while WIN027 was licensed from Qyuns Therapeutics. Windward's rights to both programs exclude Greater China and certain Asian markets.

Keep reading